PROBLEM TO BE SOLVED: To provide a method for treating cerebral amyloid angiopathy (CAA) by peripheral administration such as intravenous or subcutaneous administration in order to decrease vessel amyloid accompanied by denaturation of smooth muscle cells and extracellular matrix in vascular walls, and/or hyperplasia/hypertrophy.SOLUTION: The pharmaceutical composition comprises an antibody such as a humanized, human, or chimeric antibody which binds to a vessel amyloid beta (Aβ) for example within residues 1-5 of Aβ.
PREVENTION AND TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY